News
Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...
Pharmaceutical Technology on MSN1d
Mounjaro and Zepbound fuel strong Q2 growth for Eli LillyEli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...
Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...
23hon MSN
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Medindia on MSN2d
Zepbound Approved as First Drug for Sleep Apnea in Obese AdultsZepbound functions by targeting hormone receptors related to appetite regulation, specifically glucagon-like peptide-1 and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback